Akero Therapeutics Faces Legal Scrutiny Amid Growth Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Akero Therapeutics. Despite this, the company remains a top performer in the pharmaceutical sector, with its stock up over 80% year-to-date. Its lead drug candidate, efruxifermin, is viewed as a potential breakthrough in treating metabolic diseases.56